Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Additional Information (Details)

v3.22.1
Stockholders' Equity - Additional Information (Details)
 3 Months Ended
Jan. 01, 2022
shares
Mar. 31, 2022
USD ($)
Vote
$ / shares
shares
Mar. 31, 2021
USD ($)
shares
Dec. 31, 2021
$ / shares
shares
Jun. 09, 2021
$ / shares
shares
Nov. 30, 2020
USD ($)
Jun. 30, 2020
shares
Mar. 17, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Common stock, shares authorized   135,000,000   135,000,000 135,000,000      
Common Stock, Increase in authorized shares (in shares)         40,000,000      
Common stock, par or stated value per share | $ / shares   $ 0.0001   $ 0.0001 $ 0.0001      
Common stock, shares issued   83,801,242   77,574,405        
Common stock, shares outstanding   83,801,242   77,574,405        
Shelf registration statement, maximum authorized securities | $           $ 100,000,000    
Percentage of annual equity fee               2.50%
Issuance of common shares, net of offering costs - At-the-market offering | $   $ 8,045,000 $ 23,893,000          
Issuance of common shares - Founders Agreement | $   196,000 $ 634,000          
Shelf registration statement remaining authorized securities | $   46,400,000            
Non-vested Restricted Stock                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Total unrecognized compensation cost related to non-vested | $   $ 4,400,000            
Weighted average period (in years)   2 years 1 month 6 days            
Performance Shares                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Restricted stock outstanding non-vested   513,334            
2015 Incentive Plan                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Number of shares available for issuance Authorized             9,000,000  
Plans expires (in years)   10 years            
Shares are available for issuance   2,755,185            
At the Market Offering                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Number of shares sold   3,741,939            
Sale price per share | $ / shares   $ 2.19            
Aggregate total gross proceeds from shares sold | $   $ 8,200,000            
Net proceeds from the offering | $   $ 8,000,000.0            
Stock issued during period shares common shares for at the market offering   3,741,939            
Stock issued during period value common shares for at the market offering gross | $   $ 8,200,000            
Issuance of common shares, net of offering costs - At-the-market offering | $   8,000,000.0            
Commissions and other transaction costs | $   $ 200,000            
Fortress Biotech, Inc                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Number of shares sold 2,121,422 93,542            
Percentage of annual equity fee 2.50% 2.50%            
Issuance of common shares - Founders Agreement | $   $ 196,000            
Agent                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Commission rate   3.00%            
Common Shares                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Stock issued during period shares common shares for at the market offering   3,741,939 7,025,309          
Issuance of common shares, net of offering costs - At-the-market offering | $   $ 0 $ 1,000          
Issuance of common shares - Founders Agreement | $   $ 0 $ 0          
Common Class A                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Common stock, shares authorized         7,000,000      
Common stock, shares issued   7,000,000   7,000,000        
Common stock, shares outstanding   7,000,000   7,000,000        
Number of votes per share | Vote   1